このエントリーをはてなブックマークに追加
ID 61081
フルテキストURL
著者
Matsuda, Naoyuki Department of Emergency & Critical Care Medicine, Nagoya University Graduate School of Medicine
Nishida, Osamu Department of Anesthesiology & Critical Care Medicine, Fujita Health University School of Medicine
Taniguchi, Takumi Department of Anesthesiology & Intensive Care Medicine, Kanazawa University
Okajima, Masaki Intensive Care Unit, Kanazawa University Hospital
Morimatsu, Hiroshi Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID publons researchmap
Ogura, Hiroshi Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine
Yamada, Yoshitsugu Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital
Nagano, Tetsuji Clinical Development Planning, Ono Pharmaceutical Co., Ltd.
Ichikawa, Akira Clinical Development Planning, Ono Pharmaceutical Co., Ltd.
Kakihana, Yasuyuki Department of Emergency and Intensive Care Medicine, Kagoshima University Graduate School of Medical and Dental Sciences
J-Land 3S Study Group
抄録
Background
The J-Land 3S trial demonstrated that landiolol is effective and tolerated for treating sepsis-related tachyarrhythmias. Patient characteristics (e.g. baseline heart rate [HR], type of tachyarrhythmia, and concomitant disorders) may impact the outcomes of landiolol therapy. We performed subanalyses of J-Land 3S to evaluate the impact of patient characteristics on the efficacy and safety of landiolol for treating sepsis-related tachyarrhythmia.
Methods
Patients (≥20 years old; N = 151) hospitalised with sepsis at 54 participating hospitals in Japan with HR ≥100 beats/min for ≥10 min accompanied by diagnosis of tachyarrhythmia were randomised 1:1 to conventional sepsis therapy alone (control group) or conventional sepsis therapy plus landiolol (landiolol group). The efficacy and safety of landiolol were assessed in prespecified analyses of patients divided into subgroups by baseline characteristics and in post hoc, multivariate analyses with adjustment for age and HR at baseline.
Findings
The percentage of patients with HR of 60–94 beats/min at 24 h after randomisation (primary endpoint) was greater in the landiolol group in most subgroups in univariate unadjusted analyses and in multivariate logistic regression. The incidence of new-onset arrhythmia by 168 h and mortality by 28 days were also lower in the landiolol group in most subgroups in univariate and multivariate Cox proportional hazards models. No subgroups showed a markedly higher incidence of adverse events in univariate or multivariate logistic regression analyses.
キーワード
Ultra-short-acting β1-selective antagonist
Heart rate
Mortality
Adverse events
Septic shock
発行日
2020-11
出版物タイトル
EClinicalMedicine
28巻
出版者
Elsevier
開始ページ
100571
ISSN
2589-5370
資料タイプ
学術雑誌論文
言語
English
OAI-PMH Set
岡山大学
著作権者
© 2020 The Authors.
論文のバージョン
publisher
PubMed ID
DOI
関連URL
isVersionOf https://doi.org/10.1016/j.eclinm.2020.100571
ライセンス
http://creativecommons.org/licenses/by/4.0/